Drug Trial Radar · NCT00862641
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Sep 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,009
Actual
Start
Apr 2009
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
Conditions
- Asthma
- Coronary Artery Disease
- Pulmonary Disease, Chronic Obstructive
Interventions
RegadenosonDrug
IV
PlaceboDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline AssessmentTime frame: 2 Hours post dose
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Montgomery, Alabama
Site not named
Anaheim, California
Site not named
Encinitas, California
Site not named
Fullerton, California
Site not named
Huntington Beach, California
Site not named
Long Beach, California
Site not named
Mission Viejo, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
Santa Ana, California
Site not named
Waterbury, Connecticut
Site not named
Newark, Delaware
Site not named
Wilmington, Delaware
Site not named
Clearwater, Florida
Site not named
DeLand, Florida
Site not named
Miami, Florida
Site not named
Trinity, Florida
Site not named
Winter Park, Florida
Site not named
Stockbridge, Georgia
Site not named
Aurora, Illinois
Site not named
Topeka, Kansas
Site not named
Shreveport, Louisiana
Site not named
Auburn, Maine
Site not named
No. Dartmouth, Massachusetts
Site not named
Minneapolis, Minnesota
Site not named
Plymouth, Minnesota
Site not named
St Louis, Missouri
Site not named
Papillion, Nebraska
Site not named
Brick, New Jersey
Site not named
Raleigh, North Carolina
Site not named
Chardon, Ohio
Site not named
Cincinnati, Ohio
Site not named
Cincinnati, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Medford, Oregon
Site not named
Upland, Pennsylvania
Site not named
Providence, Rhode Island
Site not named
Charleston, South Carolina
Site not named
Easley, South Carolina
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.